On August 25, 2025 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, reported an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients (Press release, Sona Nanotech, AUG 25, 2025, View Source [SID1234655465]). The treatment and follow-up assessments of the first cohort of patients have now been completed and treatment on the second cohort of patients has been approved with Sona’s Chief Medical Officer arriving in Santiago this past weekend to oversee further treatments.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sona CMO, Dr. Carman Giacomantonio, commented, "We are very pleased with the progress of our Early Feasibility Study, which has provided rich learnings in the real-world application our THT therapy in humans. It has been a pleasure to work with the clinicians and research team at Bradford Hill. We have treated a variety of melanoma tumor types in our first cohort and have encountered no significant adverse health events in patients. As we proceed with the second cohort of patients, we have reason for optimism based on early clinical responses and tumor biopsy results for patients treated so far. We look forward to completing the targeted number of patients by the end of September and then running the more extensive scientific analysis to fully assess immune engagement in treated tumors following THT."
David Regan, Sona’s CEO, commented, "We are encouraged by the progress of our first-in-human clinical study and pleased to be progressing toward having validating clinical data that will further complement our existing preclinical data. We also excitedly anticipate additional scientific insights into our novel technology from studies planned for submission to leading scientific journals in the fall that, combined with our clinical study, will provide for a more comprehensive data package. Furthermore, with our previously announced ethics approval secured for a larger clinical trial in Canada, we are currently working to incorporate the significant learnings to date from our Early Feasibility Study into our application to Health Canada."